Arun Malhotra
Nephrology · Wilmington, DENPI 1326034893
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,348 of the $8,727 with a category attached, or 61.3%. 23 manufacturers reported payments, led by AstraZeneca at 44.7% of the total. Reporting peaked in 2019 at $3,064 and has fallen 95.8% since, to $129 in 2024.
Across 192 payments — averaging $45.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Novartis$876
- Vifor Pharma, Inc.$592
- Lilly USA, LLC$555
- Fresenius USA Marketing, Inc.$495
- Boehringer Ingelheim$478
- plus $2K from 17 others
What the payments were for
- Consulting fees$2,69631%
- Speaking & faculty fees$5556%
- Food & beverage$5,34861%
- Education$1271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 36 | $3,898 |
| Novartis | 18 | $876 |
| Vifor Pharma, Inc. | 23 | $592 |
| Lilly USA, LLC | 1 | $555 |
| Fresenius USA Marketing, Inc. | 21 | $495 |
| Boehringer Ingelheim | 9 | $478 |
| Otsuka America Pharmaceutical, Inc. | 12 | $248 |
| Amgen(2 entities) | 11 | $231 |
| Mallinckrodt Hospital Products Inc. | 6 | $210 |
| Johnson & Johnson | 5 | $186 |
| Travere Therapeutics, Inc. | 10 | $171 |
| Bayer | 8 | $144 |
| Aurinia Pharma U.S., Inc. | 4 | $102 |
| Akebia Therapeutics Inc | 6 | $100 |
| OPKO Pharmaceuticals, LLC | 6 | $89 |
| AMAG Pharmaceuticals, Inc. | 6 | $80 |
| Lexicon Pharmaceuticals, Inc. | 1 | $79 |
| Corcept Therapeutics | 1 | $50 |
| Shire North American Group Inc | 2 | $42 |
| Ultragenyx Pharmaceutical Inc. | 2 | $36 |
| GSK | 2 | $34 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Nxstage Medical, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,727 in reported general payments places this provider in the 85th percentile of 49 nephrology providers in Delaware.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Potassium Citrate ErPotassium Citrate | 62 | $5,275 |
| Chlorthalidone | 69 | $804 |
| Potassium Chloride | 13 | $559 |
| Allopurinol | 30 | $443 |
| Atorvastatin Calcium | 11 | $370 |
| Amlodipine Besylate | 30 | $340 |
| Carvedilol | 14 | $184 |
| Metoprolol Succinate | 12 | $178 |
| Indapamide | 12 | $175 |
| Calcitriol | 20 | $154 |
| Hydrochlorothiazide | 11 | $56 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Wilmington
- Ranine GhamrawiWilmington$16K
- Miroslaw ZdunekWilmington$6K
- Romil PatelWilmington$3K
- Dhruval PatelWilmington$3K
- Shalini VermaWilmington$1K
- Manish GargWilmington$981
- Brenden ConnorWilmington$587
- Arun KottaratharaWilmington$197
- Brajesh AgarwalWilmington$17
- Prayus TailorNewark$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.